Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 136-143

  Abdouh, M ^a,b   Talbot, S ^b   Couture, R ^b   Hassessian H M ^a,b,c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Bradykinin; Diabetes; Plasma extravasation; Retina

Indexed keywords

ACETYLLYSYLBRADYKININ[7 [3 (2 NAPHTHYL)ALANINE] 8 ISOLEUCINE 9 DEARGININE]; BRADYKININ; BRADYKININ[1-8]; EVANS BLUE; ICATIBANT; KININ; KININ B1 RECEPTOR; KININ B2 RECEPTOR; MESSENGER RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RAT; RECEPTOR INTRINSIC ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; VISUAL IMPAIRMENT;

EID: 42949151868     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.48     Document Type: Article

References (40)

1. Abdouh M, Khanjari A, Abdelazziz N, Ongali B, Couture R, Hasséssian HM (2003). Early up‐regulation of kinin B 1 receptors in retinal microvessels of the streptozotocin‐diabetic rat. Br J Pharmacol 140: 33–40.
2. Aoki S, Su Q, Li H, Nishikawa K, Ayukawa K, Hara Y et al. (2002). Identification of an axotomy‐induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum–Golgi stress. J Neurosci 22: 10751–10760.
3. Campos MM, Ongali B, Buck HDS, Schanstra JP, Girolami JP, Chabot JG et al. (2005). Expression and distribution of kinin B 1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin. Synapse 57: 29–37.
4. Cloutier F, Couture R (2000). Pharmacological characterization of the cardiovascular responses elicited by kinin B 1 and B 2 receptor agonists in the spinal cord of streptozotocin‐diabetic rats. Br J Pharmacol 130: 375–385.
5. Couture R, Harrisson M, Vianna RM, Cloutier F (2001). Kinin receptors in pain and inflammation. Eur J Pharmacol 429: 161–176.
6. Couture R, Girolami JP (2004). Putative roles of kinin receptors in the therapeutic effects of angiotensin 1‐converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500: 467–485.
7. D'Orléans‐Juste P, Chakir M, Berthiaume N, Plante GE (1997). Role of neutral endopeptidases in capillary dysfunctions of diabetic origin in rats. Therapie 52: 407–413.
8. Emanueli C, Grady EF, Madeddu P, Figini M, Bunnett NW, Parisi D et al. (1998). Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31: 1299–1304.
9. Gao XP, Mayhan WG, Conlon JM, Rennard SI, Rubinstein I (1993). Mechanisms of T‐kinin‐induced increases in macromolecule extravasation in vivo. J Appl Physiol 74: 2896–2903.
10. Hasséssian HM, Pogan L, Regoli D (2001). Intracellular sources account for all the Ca 2+ response evoked by bradykinin following stimulation of B 2 receptors on retinal capillary endothelial cells. In: Catravas JD, Callo AD, Ryan US, Simionescu M (eds). Vascular Endothelium: Source and Target of Inflammatory Mediators 330, pp. 362–363.
11. Hayashi I, Amano H, Ishihara K, Kumagai Y, Yoshimura H, Majima MC (2002). The role of kinin B 1 in the plasma extravasation of carrageenin‐induced pleurisy. Life Sci 70: 937–949.
12. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G et al. (1991). Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studies. Br J Pharmacol 102: 769–773.
13. Jaffa AA, Rust PF, Mayfield RK (1995). Kinin, a mediator of diabetes‐induced glomerular hyperfiltration. Diabetes 44: 156–160.
14. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner JK, Greenfield S (1994). Preventive eye care in people with diabetes is cost‐saving to the federal government. Implications for health‐care reform. Diabetes Care 17: 909–917.
15. Kuznetsova TP, Chesnokova NB, Paskhina TS (1991). Activity of tissue and plasma kallikrein and level of their precursors in eye tissue structures and media of healthy rabbits. Vopr Med Khim 37: 79–82.
16. Lawson SR, Gabra BH, Nantel F, Battistini B, Sirois P (2005a). Effects of a selective bradykinin B 1 receptor antagonist on increased plasma extravasation in streptozotocin‐induced diabetic rats: distinct vasculopathic profile of major key organs. Eur J Pharmacol 514: 69–78.
17. Lawson SR, Gabra BH, Guérin B, Neugebauer W, Nantel F, Battistini B et al. (2005b). Enhanced dermal and retinal vascular permeability in streptozotocin‐induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B 1 receptor antagonist. Regul Peptides 124: 221–224.
18. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real‐time quantitative PCR and the 2(‐delta delta C(T)) method. Methods 25: 402–408.
19. Lungu C, Dias JP, Estevão de França C, Ongali B, Regoli D, Moldovan F et al. (2007). Involvement of kinin B 1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides 41: 375–387.
20. Ma JX, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J (1996). Expression and cellular localization of the kallikrein‐kinin system in human ocular tissues. Exp Eye Res 63: 19–26.
21. Mage M, Pécher C, Neau E, Cellier E, Dos Reiss ML, Schanstra JP et al. (2002). Induction of B 1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia‐induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 80: 328–333.
22. Marceau F, Hess JF, Bachvarov DR (1998). The B 1 receptors for kinins. Pharmacol Rev 50: 357–386.
23. Moncada S (2000). Nitric oxide and cell respiration: physiology and pathology. Verh K Acad Geneeskd Belg 62: 171–179.
24. Moss SE, Klein R, Klein BE (1998). The 14‐year incidence of visual loss in a diabetic population. Ophthalmology 105: 998–1003.
25. Neroev VV, Riabina MV, Okhotsimskaia TD, Zueva MV, Tsapenko IV (2006). Use of perindopril in the treatment of patients with diabetic retinopathy. Vestn Oftalmol 122: 31–33.
26. Ongali B, Campos MM, Petcu M, Rodi D, Cloutier F, Chabot JG et al. (2004). Expression of kinin B 1 receptors in the spinal cord of streptozotocin‐diabetic rat. Neuroreport 15: 2463–2466.
27. Regoli D, Barabé J (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1–46.
28. Regoli D, Nsa Allogho S, Rizzi A, Gobeil F (1998). Bradykinin receptors and their antagonists. Eur J Pharmacol 348: 1–10.
29. Simard B, Gabra BH, Sirois P (2002). Inhibitory effect of a novel bradykinin B 1 receptor antagonist, R‐954, on enhanced vascular permeability in type 1 diabetic mice. Can J Physiol Pharmacol 80: 1203–1207.
30. Takeda H, Kimura Y, Higashida H, Yokoyama S (1999). Localization of B 2 bradykinin receptor mRNA in the rat retina and sclerocornea. Immunopharmacology 45: 51–55.
31. Vianna RMJ, Ongali B, Regoli D, Calixto JB, Couture R (2003). Up‐regulation of kinin B1 receptor in the lung of streptozotocin‐diabetic rat: autoradiographic and functional evidence. Br J Pharmacol 138: 13–22.
32. Wada R, Tifft CJ, Proia RL (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 97: 10954–10959.
33. Wille PR, Vitor R, Gabilan NH, Nicolau M (2001). Plasma extravasation mediated by lipopolysaccharide‐induction of kinin B1 receptors in rat tissues. Mediators Inflamm 10: 163–167.
34. Wirth K, Breipohl G, Stechl J, Knolle J, Henke S, Schölkens BA (1991a). Des‐Arg 9 ‐D‐Arg[Hyp 3, Thi 5, D‐Tic 7, Oic 8 ]bradykinin (des‐Arg 10 ‐[Hoe 140]) is a potent bradykinin B 1 receptor antagonist. Eur J Pharmacol 205: 217–218.
35. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H et al. (1991b). Hoe 140 a new potent and long acting bradykinin‐antagonist: in vivo studies. Br J Pharmacol 102: 774–777.
36. Xie XW, Zhao P (2004). The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice. Zhonghua Yan Ke Za Zhi 40: 770–773.
37. Zhang JZ, Gao L, Widness M, Xi X, Kern TS (2003). Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 44: 4001–4005.
38. Zheng Z, Chen H, Xu X, Li C, Gu Q (2007). Effects of angiotensin‐converting enzyme inhibitors and beta‐adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res 84: 745–752.
39. Zuccollo A, Navarro M, Catanzaro O (1996). Effects of B 1 and B 2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 74: 586–589.
40. Zuccollo A, Navarro M, Frontera M, Cueva F, Carattino M, Catanzaro OL (1999). The involvement of kallikrein‐kinin system in diabetes type I (insulitis). Immunopharmacology 45: 69–74.